Antiangiogenic Effect of on the Angiogenesis Induced by Vascular Endothelial Growth Factor (VEGF) in the Rat Cornea |
Kwon Do-hyoung
(Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University)
Jang Jae young (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Yi Na-young (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Jeong Man-bok (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Park Shin-ae (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Kim Min-su (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Nam Tchi-chou (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) Park Myung-jin (Laboratory of Cell Biology, Department of Neurosurgery, Korea Institute of Radiological and Medical Sciences, Seoul) Bae Ill-ju (Laboratory of Chonjisan Institute, Seoul) Rhee Chang-hun (Laboratory of Cell Biology, Department of Neurosurgery, Korea Institute of Radiological and Medical Sciences, Seoul) Seo Kang-moon (Department of Veterinary Surgery, College of Veterinary Medicine, Seoul National University) |
1 | Munshi N. Arsenic trioxide : An emerging therapy of multiple myeloma. Oncologist 2001; 6: 17-21 |
2 | Kim K, Li B, Winer J, Armanini M, Gillett N, Phillips H, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844 DOI ScienceOn |
3 | Lew Y, Brown S, Griffin R, Song C, Kim J. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033-6037 |
4 | Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY, Use of arsenic trioxde() in the treatment of acute promyelocytic leukemia(APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360 |
5 | Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, Yi NY, Jeong MB, Jeong SM, Nam TC, Seo KM. Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. J Vet Med Sci 2004; 66: 1091-1095 DOI ScienceOn |
6 | Jing Y, Dai J, Chalmers-Redman R. Tatton W, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111 |
7 | Lee JB, Jung SE, Lee HC, Kwon HM, Hong BK, Park HY, Kim EK, Oh JH. Effect of vascular endothelial growth factor(VEGF) on the corneal neovascularization and expression of MMP-2,9,TIMP-1,2 and flk-1. J Korean Ophthalmol Soc 2001; 42: 1053-1062 |
8 | Jin YJ, Lien WH, Tsai WC, Yang GW, Li C, Wu LW. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 2001; 4: 313-321 DOI ScienceOn |
9 | Kenyon B, Browne F, D'Amato R. Effect of thalidomide and related metabolites in a mouse corneal model of neocvascularization. Exp Eye Res 1997; 64: 971-978 DOI ScienceOn |
10 | Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674 DOI PUBMED ScienceOn |
11 | Waxman S, Anderson K. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6: 3-10 |
12 | D'Amato R, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994; 91: 4082-4085 |
13 | Soignet S, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti L, Corso D, DeBlasio A, Garbrilove J, Scheinberg D, Pandolfi P, Warrell R. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. NEJM 1998; 339: 1341-1348 DOI ScienceOn |
14 | Konig A, Wrazel L, Warrell Jr R, Rivi R, Pandolfi P, Jakubowski A, Gabrilove J, Comparative activity of melarsoprol an arsenic trioxide in chronic B-cell leukemia Lines. Blood 1997; 90: 562-570 |
15 | Park CH. Angiogenic effect of vascular endothelial growth factor on the rat cornea. Kangwon national univerity. 2003 |
16 | Roboz G, Dias S, Lam G, Lane W, Soignet S, Warrell Jr R, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530 |
17 | University of Tennessee, Department of EHS. 1997. Arsenic trioxide. http://web.utk.edu/~ehss/arsenic/arsenicb.htm |
18 | Wilson H. Miller, Jr., Hyman M. Schipper, Janet S. Lee, Jack Singer, and Samuel Waxman. Mechanisms of action of arsenic trioxide. Cancer Research 2002; 62: 3893-3903 |
19 | Antman K. Introduction : The history of arsenic trioxide in cancer therapy. Oncologist 2001; 6: 1-2 |
20 | Kenyon B, Voest E, Chen C, Flynn E, Fokman J, D'Amato R. A Model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-1632 |
21 | Fokman J, D'Amore P. Blood vessel formation : what is its molecular basis? Cell 1996; 87: 1153-1155 DOI ScienceOn |
22 | Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. International Journal of Oncology 2003; 22: 1271-1276 |
23 | Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z, Vascular endothelial growth factor(VEGF) and its receptors. FASEB J 1999; 13: 9-18 |